[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368013-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368013-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","increased-risk-of-hematologic-malignancy-in-moderate-to-severe-psoriasis-in-relation-to-the-use-of-systemic-immunosuppressants-a-nationwide-population-based-matched-cohort-study","Increased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants - A Nationwide Population-Based Matched Cohort Study","","Background: The relationship between cancer and systemic immunosuppressants used in psoriasis treatment has not been well established. The study evaluated the association between systemic immunosuppressants for moderate to severe psoriasis and the risk of certain cancers in Korean patients. Methods: A retrospective matched cohort study included 93,152 psoriasis patients and 205,850 controls using merged national health and cancer registry data from 2008 to 2018. Results: Overall cancer incidence was lower in psoriasis patients, while hematologic cancers were more frequent, especially Hodgkin’s and non-Hodgkin’s lymphoma, leukemia, and cutaneous T cell lymphoma. Higher methotrexate doses increased risks, whereas cyclosporine and corticosteroids showed no significant association with hematologic cancer incidence. Conclusion: High-dose immunosuppressant exposure is linked to increased hematologic cancer risk, supporting careful treatment management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/increased-risk-of-hematologic-malignancy-in-moderate-to-severe-psoriasis-in-relation-to-the-use-of-systemic-immunosuppressants-a-nationwide-population-based-matched-cohort-study/368013/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/increased-risk-of-hematologic-malignancy-in-moderate-to-severe-psoriasis-in-relation-to-the-use-of-systemic-immunosuppressants-a-nationwide-population-based-matched-cohort-study/368013.png","ImageObject",300,407,{"name":42,"@type":43},"OmBimo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study objective regarding psoriasis and cancer risk?","Question",{"text":63,"@type":64},"To evaluate the association between systemic immunosuppressants used for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed and what data sources were used?",{"text":68,"@type":64},"A retrospective nationwide matched cohort study included 93,152 moderate to severe psoriasis patients and 205,850 matched controls, using merged data from Korea’s National Health Insurance System, Health Insurance Review & Assessment Service, and a national cancer incidence database from 2008 to 2018.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatments showed an increased risk for hematologic cancers?",{"text":72,"@type":64},"High-dose methotrexate (≥ 17.5 mg/week) increased the risk of hematologic cancers and cutaneous T cell lymphoma, while cyclosporine and corticosteroids did not show a significant association with increased hematologic cancer incidence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368013,1790545698,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","J Korean Med Sci. 2025 Dec 15;40(48):e315 [https://doi.org/10.3346/jkms.2025.40.e315](https://doi.org/10.3346/jkms.2025.40.e315)[ ](https://doi.org/10.3346/jkms.2025.40.e315)eISSN 1598-6357·pISSN 1011-8934  \nOriginal Article  \nClinical Medicine in Other Specialties  \nReceived: Jan 22, 2025  \nAccepted: Apr 28, 2025  \nPublished online: Nov 4, 2025  \nAddress for Correspondence:  \nJung Eun Kim, MD, PhD  \nDepartment of Dermatology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 1021 Tongil-ro, Eunpyeong-gu, Seoul 03312, Korea. [Email: mdkjeun@naver.com](Email: mdkjeun@naver.com)  \nSukil Kim, MD, PhD  \nDepartment of Preventive Medicine and Public Health, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seochogu, Seoul 06591, Korea.  \nEmail: [sikimmd@catholic.ac.kr](sikimmd@catholic.ac.kr)  \n© 2025 The Korean Academy of Medical Sciences.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nYu Ri Woo  [http://orcid.org/0000-0003-2903-9534](http://orcid.org/0000-0003-2903-9534)[ ](http://orcid.org/0000-0003-2903-9534)Kyunghee Chae  [http://orcid.org/0000-0003-2030-0847](http://orcid.org/0000-0003-2030-0847)[ ](http://orcid.org/0000-0003-2030-0847)Seowon Song  [http://orcid.org/0000-0003-3315-0761](http://orcid.org/0000-0003-3315-0761)[ ](http://orcid.org/0000-0003-3315-0761)Subin Lee  [http://orcid.org/0009-0000-9557-7774](http://orcid.org/0009-0000-9557-7774)[ ](http://orcid.org/0009-0000-9557-7774)Yu Jin Lee  [http://orcid.org/0000-0001-5277-5586](http://orcid.org/0000-0001-5277-5586)  \nIncreased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants:  \nA Nationwide Population-Based Matched Cohort Study  \nYu Ri Woo ,1 Kyunghee Chae ,2 Seowon Song ,3 Subin Lee ,3 Yu Jin Lee ,3 Hoon Kang ,3 Sukil Kim ,2 and Jung Eun Kim  3  \n1Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n2Department of Preventive Medicine and Public Health, College of Medicine, The Catholic University of Korea, Seoul, Korea  \n3Department of Dermatology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea  \nABSTRACT  \nBackground: The relationship between cancer and the use of systemic immunosuppressantsin psoriasis treatment has not well established. The aim of this study was to evaluate the association between the systemic immunosuppressants used in the treatment for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis. Methods: A retrospective cohort study was conducted involving 93,152 patients with moderate to severe psoriasis and 205,850 matched controls in Korea, using merged  \ndata from the National Health Insurance System, Health Insurance Review & Assessment Service, and Korea National Cancer Incidence Database from 2008 to 2018.  \nResults: The study observed a lower incidence of any cancer in moderate to severe psoriasis patients (2.4%) compared to the general population (2.99%). However, there was a higher risk of hematologic cancers, particularly Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, and cutaneous T cell lymphoma. Notably, methotrexate doses of ≥ 17.5 mg/week increased the risk of hematologic cancer risk by 7.546 times and cutaneous T cell lymphoma risk by 9.038 times, but cyclosporine and corticosteroids use did not showa significant association with increased incidence of hematologic cancers. Meanwhile, use of cyclosporine, methotrexate and corticosteroid did not significantly affect the risk of skin cancer among patients","cbCaivntT1Jj6Y0v","https://ap.wps.com/l/cbCaivntT1Jj6Y0v","pdf",1366274,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Disease overview and treatment context","[{\"question\":\"What was the study objective regarding psoriasis and cancer risk?\",\"answer\":\"To evaluate the association between systemic immunosuppressants used for psoriasis and the risk of certain cancers in Korean patients with moderate to severe psoriasis.\"},{\"question\":\"How was the study designed and what data sources were used?\",\"answer\":\"A retrospective nationwide matched cohort study included 93,152 moderate to severe psoriasis patients and 205,850 matched controls, using merged data from Korea’s National Health Insurance System, Health Insurance Review \\u0026 Assessment Service, and a national cancer incidence database from 2008 to 2018.\"},{\"question\":\"Which treatments showed an increased risk for hematologic cancers?\",\"answer\":\"High-dose methotrexate (≥ 17.5 mg/week) increased the risk of hematologic cancers and cutaneous T cell lymphoma, while cyclosporine and corticosteroids did not show a significant association with increased hematologic cancer incidence.\"}]","Increased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants - A Nationwide Population-Based Matched Cohort Study | PDF",1790174325,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/215601630b369509a61413b977e24d3c.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8841ade552607216f246b16a40b4593.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80ddf052def0135cab348cfda13388ba.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77fbaad45dc2c465de160bf88efeb47a.webp",980,1306]